Condition: Ischemic Mitral Regurgitation · Sponsor: Laval University
This study is intended to investigate the effect of cyproheptadine (a 5HT2B receptor blocker) on mitral regurgitation severity.
This description comes directly from the study's public registry record.
Jonathan Beaudoin, MD · (418) 656-8711 · jonathan.beaudoin@criucpq.ulaval.ca
Ons Marsit, PhD · (418) 656-8711 · ons.marsit.1@ulaval.ca
Always discuss trial participation with your own doctor first.
| Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval | Québec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05469165